[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iatrogenic-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iatrogenic-injury":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100618930","the-buzdar-technique-100618930",false,"NCT07338019","The Buzdar Technique","The Buzdar Technique for Pulmonary Parenchymal Chest Tube Removal: Prospective Evaluation of a Novel Minimally Invasive Protocol","Inclusion Criteria:\n\n* Patients ≥18 years with confirmed intraparenchymal chest tube placement on chest CT or X-ray.\n* Hemodynamically stable patients suitable for conservative staged removal.\n* Patients providing informed consent.\n\nExclusion Criteria:\n\n* Patients requiring immediate thoracotomy due to massive bleeding or large bronchopleural fistula.\n* Patients with uncorrectable coagulopathy or unstable cardiopulmonary status.\n* Patients refusing participation or lost to follow-up.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","Chest tube thoracostomy remains a lifesaving intervention in trauma and thoracic surgery, used for the management of pneumothorax, hemothorax, empyema, and pleural effusions. Despite being one of the most frequently performed procedures worldwide, complication rates remain high, ranging from 20% to 40% \\[1\\]. Among these, pulmonary parenchymal chest tube (PPcT) insertion represents a rare but potentially devastating event, leading to hemorrhage, air leak, bronchopleural fistula, or infection. In Pakistan, where chest trauma and pneumothorax constitute major thoracic morbidities, PPcT cases are encountered with increasing frequency but remain underreported. Current literature describes only invasive surgical approaches-such as thoracotomy or video-assisted thoracic surgery (VATS)-for PPcT removal \\[9,10\\], with no established minimally invasive alternatives.\n\nIn response to this clinical challenge, the Department of Thoracic Surgery at (Hospital Name), Punjab, Pakistan, has developed and implemented a novel, minimally invasive three-stage removal technique, termed the Buzdar Technique, designed to ensure safe extraction of intraparenchymal chest tubes without surgical intervention. The technique follows a standardized protocol involving:\n\nHealing phase: Tube left in situ for approximately two weeks to allow localized fibrosis and stabilization of the lung parenchyma.\n\nInitial retraction: Gradual 2-cm withdrawal with optional 360° rotation under radiologic and clinical supervision, followed by 24-hour observation and chest imaging.\n\nSequential retractions: Weekly staged retractions of 2 cm until the last fenestration exits the pleural cavity, enabling safe final removal.\n\nThis prospective cohort study, conducted from July 2025 to June 2026, aims to evaluate the safety, effectiveness, and clinical outcomes of the Buzdar Technique in managing iatrogenic PPcT. Data will include patient demographics, procedural details, complications, radiologic recovery, and overall outcomes. Success will be defined as complete tube removal without pneumothorax, air leak, bleeding, or need for surgical intervention.\n\nPreliminary institutional experience over the past decade has shown excellent results, with minimal morbidity, no requirement for thoracotomy or VATS, and full radiologic recovery in the majority of patients. The expected outcomes of this prospective evaluation are to validate these findings, establish the Buzdar Technique as a reproducible, evidence-based approach, and contribute to the global literature on non-surgical management of PPcT.\n\nIf proven effective, this technique could represent a paradigm shift in the management of intraparenchymal chest tubes-offering a safe, staged, and minimally invasive alternative to surgical removal, particularly beneficial for centers in low- and middle-income countries where advanced surgical options may not always be available.",[26,27,28],"Chest Tube Management","Chest Tube Withdrawal","Iatrogenic Injury",[30,31,32,33,34],"Pulmonary parenchymal chest tube (PPcT)","chest tube malposition","tube thoracostomy complication","Buzdar technique","staged withdrawal","RECRUITING","2026-01-03",{"date":38,"type":39},"2026-01-13","ACTUAL",{"date":41,"type":39},"2025-07-01",{"date":43,"type":20},"2027-09-30",{"name":45,"class":46},"University of Health Sciences Lahore","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":47},"100522123","assessment-of-laryngopharyngeal-sensation-cancer-survivor-cohort-100522123","NCT06078527","Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort","Assessment of Laryngopharyngeal Sensation in Patients With Laryngopharyngeal Disorders","Inclusion Criteria:\n\n1. Age \\\u003C=18 years.\n2. Individuals without a laryngopharyngeal disorder (health controls) or with a laryngopharyngeal disorder. Laryngopharyngeal disorder includes but is not limited to: presbylarynx, aspiration; spasmodic dysphonia; globus pharynges; vocal fold paralysis; iatrogenic injury to the larynx; muscle tension dysphonia; neurogenic dysphagia; laryngeal sensory neuropathy; and laryngopharyngeal disorders resulting from prior radiation therapy in individuals with a history of head and neck cancer who have completed radiation therapy as primary or adjuvant cancer treatment\n3. Ability and willingness to comply with study procedures.\n4. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Non-English speaking.\n2. Laryngopharyngeal structures are not accessible on exam.\n3. Known contraindication to any study-related procedure, or history of being unable to tolerate laryngoscopy.\n4. Vocal fold immobility or severe hypomobility on adduction.\n5. For head and neck cancer survivors only: Currently undergoing radiation therapy for head and neck cancer (i.e., primary\u002Fadjuvant radiation therapy treatment plan is not yet completed).","85 Years",{"count":57,"type":20},40,[23],"A previous study completed in 2022 (NCT05158179) was conducted using cohorts of healthy controls, and adults with general laryngopharyngeal disorders. This study will expand on the previous research to include a separate cohort of adults being seen in clinic for an existing laryngopharyngeal disorder resulting from previous radiation or other cancer treatments.",[61,62,63,64,65,66,67,28,68],"Presbylarynx","Aspiration","Spasmodic Dysphonia","Globus Pharyngeus","Larynx Paralysis","Laryngeal Disease","Vocal Cord Paralysis","Sensory Neuropathy",[70,71,72],"Cancer survivors","Previous cancer treatment","Laryngopharyngeal disorders","NOT_YET_RECRUITING","2025-07-21",{"date":76,"type":39},"2025-07-23",{"date":78,"type":20},"2025-10-01",{"date":80,"type":20},"2028-01-31",{"name":82,"class":46},"University of California, San Francisco"]